Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support

At FDLI, both US FDA acting Commissioner Stephen Ostroff and BIO’s Kay Holcombe strike note of anticipating positive outcomes for FDA, despite current political and regulatory uncertainties. FDA has been through challenges before, and “we have come through them even stronger," Ostroff assures meeting.

The threat of Trump administration proposals to slash funding for FDA and the National Institutes of Health may in the end result in more energetic support among legislators and others for those programs, Kay Holcombe, senior vice president of science policy at the Biotechnology Innovation Organization suggests.

Speaking May 4 at the Food and Drug Law Institute’s annual conference in Washington, Holcombe took a somewhat neutral tone...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership